Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1093/jac/dkz156 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Evolution of ceftazidime-avibactam and cefiderocol resistance in ST131-H30R1- isolates with KPC-3 mutants and application of FTIR biotyping.
Microbiol Spectr
April 2024
Servicio de Microbiología, Hospital Universitario Ramón y Cajal and Instituto Ramón y Cajal de Investigación Sanitaria (IRYCIS), Madrid, Spain.
Ceftazidime-avibactam and cefiderocol represent two of the few alternatives for infections by KPC-producing Enterobacterales. We reported the emergence of resistance to both ceftazidime-avibactam and cefiderocol in a KPC-producing ST131- (KPC-ST131-) clinical isolate. Antimicrobial susceptibility testing, Fourier-transform infrared (FTIR) spectroscopy, whole-genome sequencing, and cloning experiments were performed.
View Article and Find Full Text PDFCeftazidime-avibactam: are we safe from class A carbapenemase producers' infections?
Folia Microbiol (Praha)
December 2021
Programa de Pós-Graduação Em Ciências Farmacêuticas, Faculdade de Farmácia, Universidade Federal Do Rio Grande Do Sul, Avenida Ipiranga, Porto Alegre, RS, 2752, 90610-000, Brazil.
Recently, new combinations of β-lactams and β-lactamase inhibitors became available, including ceftazidime-avibactam, and increased the ability to treat infections caused by carbapenem-resistant Enterobacterales (CRE). Despite the reduced time of clinical use, isolates expressing resistance to ceftazidime-avibactam have been reported, even during treatment or in patients with no previous contact with this drug. Here, we detailed review data on global ceftazidime-avibactam susceptibility, the mechanisms involved in resistance, and the molecular epidemiology of resistant isolates.
View Article and Find Full Text PDFEvolutionary Trajectories toward Ceftazidime-Avibactam Resistance in Klebsiella pneumoniae Clinical Isolates.
Antimicrob Agents Chemother
September 2021
Department of Public Health and Infectious Diseases, Sapienza University of Romegrid.7841.a, Rome, Italy.
From January 2019 to April 2020, 32 KPC-producing, ceftazidime-avibactam (CZA)-resistant Klebsiella pneumoniae strains were isolated in a university hospital in Rome, Italy. These strains belonged to the sequence type 512 (ST512), ST101, and ST307 high-risk clones. Nine different CZA-resistant KPC-3 protein variants were identified, five of them never previously reported (KPC-66 to KPC-70).
View Article and Find Full Text PDFCross-resistance to cefiderocol and ceftazidime-avibactam in KPC β-lactamase mutants and the inoculum effect.
Clin Microbiol Infect
August 2021
IAME, UMR 1137, INSERM, Université de Paris, AP-HP, France; Laboratoire de Microbiologie, Hôpital Robert Debré, AP-HP, 75019 Paris, France. Electronic address:
Objectives: Ceftazidime-avibactam (CZA) and cefiderocol are recently commercialized molecules active against highly drug-resistant bacteria, including carbapenem-resistant members of the Enterobacteriaceae. Mutants resistant to CZA have been described, notably in Klebsiella pneumoniae carbapenemase (KPC) producers. Considering the structural similarities between ceftazidime and cefiderocol, we hypothesized that resistance to CZA in KPC-producing members of the Enterobacterales may lead to cross-resistance to cefiderocol.
View Article and Find Full Text PDFKPC-31 expressed in a ceftazidime/avibactam-resistant Klebsiella pneumoniae is associated with relevant detection issues.
J Antimicrob Chemother
August 2019
Department of Experimental and Clinical Medicine, University of Florence, Florence, Italy.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!